FinalDose develops programmable DNA therapeutics that eliminate diseased cells by targeting pathogenic genetic sequences.
FinalDose's investors include Y Combinator, Founder Factor.
FinalDose is headquartered in Altrincham, United Kingdom.
FinalDose develops programmable DNA therapeutics that eliminate diseased cells by targeting pathogenic genetic sequences.
FinalDose is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"FinalDose — Funding & Investors." VCBacked, June 16, 2026, https://www.vcbacked.co/company/finaldose. Accessed November 13, 2026.
VCBacked. (2026). FinalDose — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/finaldose
{{cite web |title=FinalDose — Funding & Investors |url=https://www.vcbacked.co/company/finaldose |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at FinalDose? Request a listing update